«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2021 05

Page:

868-871

Research Field:

Publishing date:

Info

Title:

Efficacy and safety of fosaprepitant in patient with nausea and vomiting caused by chemotherapy

Author(s):

DING Jie; WANG Juan; WANG Li; WANG Keming

Department of Oncology,the Second Affiliated Hospital of Nanjing Medical University,Jiangsu Nanjing 210011,China.

Keywords:

fosaprepitant; cisplatin; chemotherapy-induced nausea and vomiting

PACS:

R730.5

DOI:

10.3969/j.issn.1672-4992.2021.05.033

Abstract:

Objective:To observe the efficacy and safety of fosaprepitant in reducing chemotherapy-induced nausea and vomiting.Methods:62 patients of cancer patients who received chemotherapy of cisplatin contained regimen were randomly divided into observation group and control group.The observation group was treated with fosaprepitant and palonosetron combined with dexamethasone.The control group was treated with palonosetron and dexamethasone.The effect and adverse reaction of two groups on preventing nausea and vomiting were observed.Results:The control rate of nausea in observation group was 87.1%,which was better than that in control group 48.4% (P£¼0.05).The complete remission rate of acute and delayed vomiting in the observation group was 80.6% and 77.4%,respectively,which was better than 58.1% and 54.8% in the control group (P£¼0.05).The main adverse reactions in the two groups were fatigue,diarrhea,constipation,insomnia,vertigo,local pain at the injection site and so on,all of which were mild.Conclusion:Fosaprepitant has obvious preventive effect on nausea and vomiting caused by cisplatin-containing chemotherapy,and the adverse reaction is mild and tolerable,which is worthy of clinical popularization.

References:

£Û1£ÝNATALE JJ.Overview of the prevention and management of CINV£ÛJ£Ý.The American Journal of Managed Care,2018,24(18):391-397.
£Û2£ÝSOEFJE SA.Strategies to improve CINV outcomes in managed care£ÛJ£Ý.The American Journal of Managed Care,2018,24(18):398-404.
£Û3£ÝHESKETH PJ,BOHLKE K,LYMAN GH,et al.Antiemetics:American Society of Clinical Oncology focused guideline update£ÛJ£Ý.Journal of Clinical Oncology,2016,34(4):381-386.
£Û4£ÝRAZVI Y,CHAN S,MCFARLANE T,et al.ASCO,NCCN,MASCC/ESMO:a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients£ÛJ£Ý.Supportive Care in Cancer,2019,27(1):87-95.
£Û5£ÝKARTHAUS M,SCHIEL X,RUHLMANN CH,et al.Neurokinin-1 receptor antagonists:review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults£ÛJ£Ý.Expert Review of Clinical Pharmacology,2019,12(7):661-680.
£Û6£ÝCHOW R,TSAO M,CHIU L,et al.Efficacy of the combination neurokinin-1 receptor antagonist,palonosetron,and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting:a systematic review and meta-analysis of randomized controlled trials£ÛJ£Ý.Annals of Palliative Medicine,2018,7(2):221-233.
£Û7£ÝRAPOPORT BL,JORDAN K,WEINSTEIN C.Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting:focus on fosaprepitant£ÛJ£Ý.Future Oncology,2018,14(1):77-92.
£Û8£ÝCLARK-SNOW RA,VIDALL C,B¦ZRJESON S,et al.Fixed combination antiemetic:A literature review on prevention of chemotherapy-induced nausea and vomiting using netupitant/palonosetron£ÛJ£Ý.Clinical Journal of Oncology Nursing,2018,22(2):52-63.
£Û9£ÝMASTRANGELO M.Cisplatin-based therapy and CINV:Optimal antiemetics during germ cell testicular cancer treatment£ÛJ£Ý.Clinical Journal of Oncology Nursing,2018,22(2):31-36.
£Û10£ÝRICHARDSON JL,MARKS G,LEVINE A.The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy£ÛJ£Ý.Journal of Clinical Oncology,1988,6(11):1746-1752.
£Û11£ÝAAPRO M.CINV:still troubling patients after all these years£ÛJ£Ý.Supportive Care in Cancer,2018,26(1):5-9.
£Û12£ÝGADAIS C,BALLET S.The neurokinins:Peptidomimetic ligand design and therapeutic applications£ÛJ£Ý.Current Medicinal Chemistry,2020,27(9):1515-1561.
£Û13£ÝJANICKI PK.Management of acute and delayed chemotherapy-induced nausea and vomiting:role of netupitant-palonosetron combination£ÛJ£Ý.Therapeutics and Clinical Risk Management,2016,12:693-699.
£Û14£ÝCARLSON RW,LARSEN JK,MCCLURE J,et al.International adaptations of NCCN Clinical Practice Guidelines in Oncology£ÛJ£Ý.Journal of the National Comprehensive Cancer Network:JNCCN,2014,12(5):643-648.
£Û15£ÝIIHARA H,SHIMOKAWA M,ABE M,et al.Study protocol for an open-label,single-arm,multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients£ÛJ£Ý.BMJ Open,2019,9(1):e024357.
£Û16£ÝMORA J,VALERO M,DICRISTINA C,et al.Pharmacokinetics/pharmacodynamics,safety,and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients£ÛJ£Ý.Pediatric Blood & Cancer,2019,66(6):e27690.
£Û17£ÝYANG LQ,SUN XC,QIN SK,et al.Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people:A randomized,double-blind,phase III study£ÛJ£Ý.European Journal of Cancer Care,2017,26(6)£º256-257.
£Û18£ÝWEINSTEIN C,JORDAN K,GREEN SA,et al.Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy:results of a randomized,double-blind phase III trial£ÛJ£Ý.Annals of Oncology,2016,27(1):172-178.
£Û19£Ýʦºë,ºØÐÂ,Àîºì,µÈ.¸£É³Æ¥Ì¹ÈýÁªÓÃÒ©Ô¤·À¸ßÖÂÍ»¯ÁÆ·½°¸ËùÖ¶ñÐÄÅ»ÍÂÁÆЧµÄÁÙ´²¹Û²ì£ÛJ£Ý.ÏÖ´úÖ×Áöҽѧ,2018,26(24)£º4018-4021. SHI Hong,HE Xin,LI Hong,et al.Clinical effect of fosaprepitant in the prevention of nausea and vomiting caused by high vomiting chemotherapy regimen£ÛJ£Ý.Modern Oncology,2018,26(24)£º4018-4021.
£Û20£ÝSAITO H,YOSHIZAWA H,YOSHIMORI K,et al.Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin:a multicentre,randomised,double-blind,placebo-controlled phase 3 trial£ÛJ£Ý.Annals of Oncology,2013,24(4):1067-1073.
£Û21£ÝWILLIER S,CABANILLAS STANCHI KM,VON HAVE M,et al.Efficacy,safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy-results of a non-interventional observation study£ÛJ£Ý.BMC Cancer,2019,19(1):1118.
£Û22£ÝSHILLINGBURG A,BIONDO L.Aprepitant and fosaprepitant use in children and adolescents at an academic medical center£ÛJ£Ý.The Journal of Pediatric Pharmacology and Therapeutics,2014,19(2):127-131.
£Û23£ÝSAITO Y,KUMAMOTO T,ARIMA T,et al.Evaluation of aprepitant and fosaprepitant in pediatric patients£ÛJ£Ý.Pediatrics International,2019,61(3):235-239.
£Û24£ÝRADHAKRISHNAN V,JOSHI A,RAMAMOORTHY J,et al.Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children:A double-blind,placebo-controlled,phase III randomized trial£ÛJ£Ý.Pediatr Blood Cancer,2019,66(3):e27551.

Memo

Memo:

National Natural Science Foundation of China£¨No.81802373£©;¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÇàÄêÏîÄ¿×ÊÖú£¨±àºÅ£º81802373£©£»ÄϾ©Ò½¿Æ´óѧµÚ¶þ¸½ÊôÒ½Ôº789׿ԽÈ˲ÅÏîÄ¿×ÊÖú£¨±àºÅ£º789ZYRC202090147£©

Common functions

Last Update: 2021-01-29